Despite significantly improved outcomes with anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors, approximately half of patients with advanced melanoma will not achieve a durable response and face a high risk of recurrence and death (1). This evidence concerns the gene CTLA4 and melanoma.